Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2008 | 2 |
2009 | 2 |
2011 | 1 |
2018 | 1 |
2024 | 0 |
Search Results
5 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral oestrogen or combined androgen deprivation of 915 patients with metastasized prostate cancer: evaluation of cardiovascular events in a randomized trial.
Scand J Urol Nephrol. 2011 Nov;45(5):346-53. doi: 10.3109/00365599.2011.585820. Epub 2011 May 31.
Scand J Urol Nephrol. 2011.
PMID: 21627403
Clinical Trial.
Clinical and prognostic significance of changes in haemoglobin concentration during 1 year of androgen-deprivation therapy for hormone-naïve bone-metastatic prostate cancer.
Ebbinge M, Berglund A, Varenhorst E, Hedlund PO, Sandblom G; Scandinavian Prostate Cancer Group (SPCG)-5 Study Group.
Ebbinge M, et al.
BJU Int. 2018 Oct;122(4):583-591. doi: 10.1111/bju.14227. Epub 2018 May 30.
BJU Int. 2018.
PMID: 29611275
Clinical Trial.
Item in Clipboard
Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P, Lund JA, Tasdemir I, Hoyer M, Wiklund F, Fosså SD; Scandinavian Prostate Cancer Group Study 7; Swedish Association for Urological Oncology 3.
Widmark A, et al.
Lancet. 2009 Jan 24;373(9660):301-8. doi: 10.1016/S0140-6736(08)61815-2. Epub 2008 Dec 16.
Lancet. 2009.
PMID: 19091394
Free article.
Clinical Trial.
Item in Clipboard
Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5.
Hedlund PO, Damber JE, Hagerman I, Haukaas S, Henriksson P, Iversen P, Johansson R, Klarskov P, Lundbeck F, Rasmussen F, Varenhorst E, Viitanen J; SPCG-5 Study Group.
Hedlund PO, et al.
Scand J Urol Nephrol. 2008;42(3):220-9. doi: 10.1080/00365590801943274.
Scand J Urol Nephrol. 2008.
PMID: 18432528
Clinical Trial.
Item in Clipboard
Quality of life in patients with locally advanced prostate cancer given endocrine treatment with or without radiotherapy: 4-year follow-up of SPCG-7/SFUO-3, an open-label, randomised, phase III trial.
Fransson P, Lund JA, Damber JE, Klepp O, Wiklund F, Fosså S, Widmark A; Scandinavian Prostate Cancer Group Study 7; Swedish Association for Urological Oncology 3.
Fransson P, et al.
Lancet Oncol. 2009 Apr;10(4):370-80. doi: 10.1016/S1470-2045(09)70027-0. Epub 2009 Mar 13.
Lancet Oncol. 2009.
PMID: 19286422
Clinical Trial.
Item in Clipboard
Cite
Cite